Dr Reddy's Q1 net at 1,188 crore, up 108% from Q1-FY21
Company to tap new opportunities in end-to-end disease management offerings and biologicals28-07-2022
28-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Unaudited Financial Results For The Quarter Ended June 30, 2022
Unaudited Financial Results for the quarter ended June 30, 202228-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Grant Of Stock Options To The Eligible Employees Under The Employee Stock Options Schemes Of The Company.
Grant of Stock Options to the eligible employees under the Employee Stock Options Schemes of the Company.28-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 7,426 equity shares of Rs. 5/- each of the Company, fully paid up.28-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Arun Madhavan Kumar (DIN: 09665138) as an Additional Director, categorized as Independent, on the Board of the Company.28-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Arun Madhavan Kumar (DIN: 09665138) as an Additional Director, categorized as Independent, on the Board of the Company.28-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2022.
Unaudited Financial Results for the quarter ended June 30, 202228-07-2022
Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts
Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.27-07-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy''s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market27-07-2022
Dr Reddy's launches new product in US
Fexofenadine and Pseudoephedrineextended release tablets are store-brand equivalent of Allegra-D 24 HR in the US marketwere launched22-07-2022